摘要Breast cancer is a heterogeneous disease stratified by hor-mone receptors(HRs)and human epidermal growth factor receptor 2(HER2)status and each subtype has divergent therapeutic needs.Despite the current therapeutic advances,resistance to standard therapies remains pervasive,under-scoring the demand for novel strategies.Antibody-drug conjugates(ADCs)offer a powerful strategy by combining tumor-specific antibodies to potent cytotoxins,enabling selec-tive delivery and minimizing off-target toxicity1.TROP2,a transmembrane glycoprotein broadly overexpressed in breast cancer,has emerged as a promising ADC target.The approval of datopotamab deruxtecan(Dato-DXd)with sacituzumab govitecan(SG)and the incorporation of these ADCs into the National Comprehensive Cancer Network(NCCN)guide-lines(v2.2025)highlight the fast penetration of TROP2 ADCs into clinical practice2.This editorial provides timely insights into optimizing TROP2-targeted strategies to improve out-comes across breast cancer subtypes.